TY - JOUR
T1 - Management of patients with lung cancer and poor performance status
AU - Gajra, Ajeet
AU - Marr, Alissa S.
AU - Ganti, Apar Kishor
PY - 2014/7/1
Y1 - 2014/7/1
N2 - Patients who are able to care for themselves but are unable to perform most work-related activities are considered to have a poor performance status (PS). Individuals who fulfill these criteria constitute a significant proportion of all patients with lung cancer. Patients with lung cancer and a poor PS, irrespective of age, have an increased incidence of adverse effects with therapy and poorer outcomes. Thus, although these individuals must be treated differently, data on optimal approaches for these patients are lacking, because this cohort is underrepresented in conventional clinical trials due to enrollment restrictions. This article presents the available evidence on the treatment of this group of patients with lung cancer. Although patients with PS 2 have worse overall outcomes than those with good PS, a selected proportion may still benefit from standard therapy. Further trials are needed to identify optimal strategies to treat this group of patients with lung cancer.
AB - Patients who are able to care for themselves but are unable to perform most work-related activities are considered to have a poor performance status (PS). Individuals who fulfill these criteria constitute a significant proportion of all patients with lung cancer. Patients with lung cancer and a poor PS, irrespective of age, have an increased incidence of adverse effects with therapy and poorer outcomes. Thus, although these individuals must be treated differently, data on optimal approaches for these patients are lacking, because this cohort is underrepresented in conventional clinical trials due to enrollment restrictions. This article presents the available evidence on the treatment of this group of patients with lung cancer. Although patients with PS 2 have worse overall outcomes than those with good PS, a selected proportion may still benefit from standard therapy. Further trials are needed to identify optimal strategies to treat this group of patients with lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=84903945876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903945876&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2014.0098
DO - 10.6004/jnccn.2014.0098
M3 - Article
C2 - 24994922
AN - SCOPUS:84903945876
SN - 1540-1405
VL - 12
SP - 1015
EP - 1025
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 7
ER -